NeOnc posts Q3 results, confirms positive Phase 2a data for NEO100 ahead of SNO
The company reported a narrower net loss, a $15 million raise and preferred stock redemption, and said updated NEO100 and NEO212 data will be shown at SNO on November 13.
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) reported financial results for the third quarter ended September 30, 2026 in a Form 8-K dated November 5, 2026, alongside updates on its two CNS cancer programs.
The company said it reported positive topline results in August from the Phase 2a portion of NEO100-01, evaluating intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, with the study meeting its primary endpoint of six-month progression-free survival at 48.9% against a pre-specified 20% benchmark for standard of care (p = 0.0047)1. Median overall survival was 26.09 months, with overall survival rates of 60.9% at 12 months and 54.1% at 24 months, and no major toxicities were reported, with adverse events predominantly low grade.1
For NEO212, the company said that in July it received written feedback from the FDA on chemistry, manufacturing and controls for the program, covering a planned shift from a capsule to a tablet formulation, which NeOnc is folding into its development plan for the drug.1
Both programs will be discussed in posters at the Society for Neuro-Oncology's 31st Annual Meeting. Thomas C. Chen, MD, PhD, will present updated results from the Phase 1/2a study and compassionate use experience with intranasal NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma, and Josh Neman, PhD, will present Phase 1 safety, pharmacokinetic and early activity data for oral NEO212 in TMZ-resistant recurrent glioblastoma and brain metastases.1
On corporate matters, NeOnc and the Department of Health – Abu Dhabi signed a memorandum of understanding in October to work together on CNS oncology research, clinical development approaches, real-world evidence, and training, and to explore a possible clinical collaboration and regional presence for NeOnc, pending separate agreements and approvals.1
On financials, the company closed a registered direct offering on September 10, 2026 priced at-the-market under Nasdaq rules, raising about $15 million before fees1, and used part of the proceeds to redeem all 6,000 outstanding shares of its Series A Convertible Preferred Stock for about $5.8 million in cash, a discount to its $6.0 million stated value, issuing no common stock in the process.1 Cash and cash equivalents stood at about $6.2 million as of September 30, 2026, up from about $2.0 million at June 30, 2026.1 Net loss for the quarter was $4.4 million, compared with $8.6 million in the third quarter of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.